Inhibition of inducible nitric oxide synthase by bis(helenalinyl)glutarate in RAW264.7 macrophages

Biochemical Pharmacology

Volumn 79, Issue 11, 2010, Pages 1573-1580

  Konkimalla, V Badireenath ^a   Blunder, Martina ^b   Bauer, Rudolf ^b   Efferth, Thomas ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cytotoxicity; Glucocorticoid receptor signaling pathway; Griess assay; Interleukin 10 signaling pathway; Microarrays; Nitric oxide

Indexed keywords

BIS(HELENALINYL)GLUTARATE; GLUCOCORTICOID RECEPTOR; GLUTARIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION; GROWTH INHIBITION; IC 50; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYTOCHEMISTRY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INTERLEUKIN-1; INTERLEUKIN-10; LACTONES; MACROPHAGES; METABOLIC NETWORKS AND PATHWAYS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, GLUCOCORTICOID; SESQUITERPENES;

EID: 77950098196     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.01.020     Document Type: Article

References (60)

1. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994, 343:1199-1206.
2. Lechner M., Lirk P., Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005, 15:277-289.
3. Wink D.A., Kasprzak K.S., Maragos C.M., Elespuru R.K., Misra M., Dunams T.M., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991, 254:1001-1003.
4. Schmutte C., Rideout W.M., Shen J.C., Jones P.A. Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double stranded DNA. Carcinogenesis 1994, 15:2899-2903.
5. Felley-Bosco E. Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis Rev 1998, 17:25-37.
6. Li C.Q., Trudel L.J., Wogan G.N. Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53. Proc Natl Acad Sci USA 2002, 99:10364-10369.
7. Sawa T., Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 2006, 14:91-100.
8. Murakami A., Ohigashi H. Targeting NOX, iNOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer 2007, 121:2357-2363.
9. Perwez Hussain S., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121:2373-2380.
10. Ridnour L.A., Thomas D.D., Donzelli S., Espey M.G., Roberts D.D., Wink D.A., et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006, 8:1329-1337.
11. Bentz B.G., Haines G.K., Lingen M.W., Pelzer H.J., Hanson D.G., Radosevich J.A. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol 1999, 108:781-787.
12. Tanaka H., Kijima H., Tokunaga T., Tajima T., Himeno S., Kenmochi T., et al. Frequent expression of inducible nitric oxide synthase in esophageal squamous cell carcinomas. Int J Oncol 1999, 14:1069-1073.
13. Jang T.J., Kim D.K. Inducible nitric oxide synthase expression of tumor and stromal cells is associated with the progression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Cancer Lett 2002, 182:121-126.
14. Franco L., Doria D., Bertazzoni E., Benini A., Bassi C. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat 2004, 73:51-58.
15. Speranza L., De Lutiis M.A., Shaik Y.B., Felaco M., Patruno A., Tetè A., et al. Localization and activity of iNOS in normal human lung tissue and lung cancer tissue. Int J Biol Markers 2007, 22:226-231.
16. Chen H.H., Su W.C., Chou C.Y., Guo H.R., Ho S.Y., Que J., et al. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:1093-1100.
17. Li L.G., Xu H.N. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol 2005, 11:2539-2544.
18. Wang L., Shi G.G., Yao J.C., Gong W., Wei D., Wu T.T., et al. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 2005, 8:18-28.
19. Ekmekcioglu S., Ellerhorst J.A., Prieto V.G., Johnson M.M., Broemeling L.D., Grimm E.A. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006, 119:861-866.
20. Badn W., Hegardt P., Fellert M.A., Darabi A., Esbjörnsson M., Smith K.E., et al. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. Scand J Immunol 2007, 65:289-297.
21. Frederiksen L.J., Sullivan R., Maxwell L.R., Macdonald-Goodfellow S.K., Adams M.A., Bennett B.M., et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signalling. Clin Cancer Res 2007, 13:2199-2206.
22. Hirst D.G., Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007, 12:3406-3418.
23. Calixto J.B., Campos M.M., Otuki M.F., Santos A.R. Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 2004, 70:93-103.
24. Wang C.C., Huang Y.J., Chen L.G., Lee L.T., Yang L.L. Inducible nitric oxide synthase inhibitors of Chinese herbs III. Rheum palmatum. Planta Med 2002, 68:869-874.
25. Dirsch V.M., Stuppner H., Vollmar A.M. The Griess assay: suitable for a bio-guided fractionation of anti-inflammatory plant extracts?. Planta Med 1998, 64:423-426.
26. Park H.J., Kim R.G., Seo B.R., Ha J., Ahn B.T., Bok S.H., et al. Saucernetin-7 and saucernetin-8 isolated from Saururus chinensis inhibit the LPS-induced production of nitric oxide and prostaglandin E2 in macrophage RAW264.7 cells. Planta Med 2003, 69:947-950.
27. Yun J.M., Kwon H., Hwang J.K. In vitro anti-inflammatory activity of panduratin A isolated from Kaempferia pandurata in RAW264.7 cells. Planta Med 2003, 69:1102-1108.
28. Jang S.I., Jeong S.I., Kim K.J., Kim H.J., Yu H.H., Park R., et al. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7 cells. Planta Med 2003, 69:1057-1059.
29. Jiang D.J., Jiang J.L., Tan G.S., Huang Z.Z., Deng H.W., Li Y.J. Demethylbellidifolin inhibits adhesion of monocytes to endothelial cells via reduction of tumor necrosis factor alpha and endogenous nitric oxide synthase inhibitor level. Planta Med 2003, 69:1150-1152.
30. Radtke O.A., Kiderlen A.F., Kayser O., Kolodziej H. Gene expression profiles of inducible nitric oxide synthase and cytokines in Leishmania major-infected macrophage-like RAW 264.7 cells treated with gallic acid. Planta Med 2004, 70:924-928.
31. Won J.H., Kim J.Y., Yun K.J., Lee J.H., Back N.I., Chung H.G., et al. Gigantol isolated from the whole plants of Cymbidium goeringii inhibits the LPS-induced iNOS and COX-2 expression via NF-kappaB inactivation in RAW 264.7 macrophages cells. Planta Med 2006, 72:1181-1187.
32. Lin C.M., Huang S.T., Liang Y.C., Lin M.S., Shih C.M., Chang Y.C., et al. Isovitexin suppresses lipopolysaccharide-mediated inducible nitric oxide synthase through inhibition of NF-kappa B in mouse macrophages. Planta Med 2005, 71:748-753.
33. Ko H.C., Kuo Y.H., Wei B.L., Chiou W.F. Laxifolone A suppresses LPS/IFN-gamma-induced NO synthesis by attenuating NF-kappaB translocation: role of NF-kappaB p105 level. Planta Med 2005, 71:514-519.
34. Jin X.Y., Lee S.H., Kim J.Y., Zhao Y.Z., Park E.J., Lee B.S., et al. Polyozellin inhibits nitric oxide production by down-regulating LPS-induced activity of NF-kappaB and SAPK/JNK in RAW 264.7 cells. Planta Med 2006, 72:857-859.
35. Park K.M., Kim Y.S., Jeong T.C., Joe C.O., Shin H.J., Lee Y.H., et al. Nitric oxide is involved in the immunomodulating activities of acidic polysaccharide from Panax ginseng. Planta Med 2001, 67:122-126.
36. Kolodziej H., Kayser O., Kiderlen A.F., Ito H., Hatano T., Yoshida T., et al. Antileishmanial activity of hydrolyzable tannins and their modulatory effects on nitric oxide and tumour necrosis factor-alpha release in macrophages in vitro. Planta Med 2001, 67:825-832.
37. Guerrero M.F., Puebla P., Martín M.L., Carrón R., San Román L., Reguero M.T., et al. Inhibitory effect of N(G)-nitro-l-arginine methyl ester on the anti-adrenergic response elicited by ayanin in the pithed rat. Planta Med 2002, 68:322-325.
38. Lahlou S., Magalhães P.J., Carneiro-Leão R.F., Leal-Cardoso J.H. Involvement of nitric oxide in the mediation of the hypotensive action of the essential oil of Mentha×villosa in normotensive conscious rats. Planta Med 2002, 68:694-699.
39. Estrada S., Rojas A., Mathison Y., Israel A., Mata R. Nitric oxide/cGMP mediates the spasmolytic action of 3,4′-dihydroxy-5,5′-dimethoxybibenzyl from Scaphyglottis livida. Planta Med 1999, 65:109-114.
40. Konkimalla V.B., Efferth T. Anti-cancer natural product library from traditional chinese medicine. Comb Chem High Throughput Screen 2008, 11:7-15.
41. Lee K.H., Ibuka T., Sims D., Muraoka O., Kiyokawa H., Hall I.H., et al. Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents. J Med Chem 1981, 24:924-927.
42. Jorens P.G., Matthys K.E., Bult H. Modulation of nitric oxide synthase activity in macrophages. Mediators Inflamm 1995, 4:75-89.
43. Kleinert H., Schwarz P.M., Förstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem 2003, 384:1343-1364.
44. Konkimalla V.B., Blunder M., Korn B., Soomro S.A., Jansen H., Chang W., et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008, 19:184-191.
45. Baer H.P., Schmidt K., Mayer B., Kukovetz W.R. Pentamidine does not interfere with nitrite formation in activated RAW 264.7 macrophages but inhibits constitutive brain nitric oxide synthase. Life Sci 1995, 57:1973-1980.
46. Wippel R., Rehn M., Gorren A.C.F., Schmidt K., Mayer B. Interference of the polyphenol epicatechin with the biological chemistry of nitric oxide- and peroxynitrite-mediated reactions. Biochem Pharmacol 2004, 67:1285-1295.
47. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity using human and other tumor cell lines. Cancer Res 1988, 48:4827-4833.
48. Eberwine J., Yeh H., Miyashiro K., Cao Y., Nair S., Finnel R. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 1992, 89:3010-3014.
49. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 2004, 23:4993-5003.
50. Comtois S.L., Gidley M.D., Kelly D.J. Role of the thioredoxin system and the thiol-peroxidases Tpx and Bcp in mediating resistance to oxidative and nitrosative stress in Helicobacter pylori. Microbiology 2003, 149(Pt 1):121-129.
51. Calabrese V., Sultana R., Scapagnini G., Guagliano E., Sapienza M., Bella R., et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 2006, 8:1975-1986.
52. Sun Y., Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008, 68:8269-8277.
53. Sohn K.C., Jang S., Choi D.K., Lee Y.S., Yoon T.J., Jeon E.K., et al. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochem Biophys Res Commun 2007, 356:810-815.
54. Fernandes D., Duma D., Assreuy J. Steroids and nitric oxide in sepsis. Front Biosci 2008, 13:1698-1710.
55. Boyer A., Chadda K., Salah A., Annane D. Glucocorticoid treatment in patients with septic shock: effects on vasopressor use and mortality. Int J Clin Pharmacol Ther 2006, 44:309-318.
56. Goldfarb R.D., Cinel I. Inhaled nitric oxide therapy for sepsis: more than just lung. Crit Care Med 2007, 35:290-292.
57. Suzuki H. New insight from the interplay between nitric oxide and glucocorticoids. Crit Care Med 2004, 32:2362-2363.
58. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 2004, 1:255-263.
59. James S.L. Role of nitric oxide in parasitic infections. Microbiol Rev 1995, 59:533-547.
60. Ogawa Y., Duru E.A., Ameredes B.T. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 2008, 8:437-445.